These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 28130604)

  • 21. Potential of nanoparticles for allergen-specific immunotherapy - use of silica nanoparticles as vaccination platform.
    Scheiblhofer S; Machado Y; Feinle A; Thalhamer J; Hüsing N; Weiss R
    Expert Opin Drug Deliv; 2016 Dec; 13(12):1777-1788. PubMed ID: 27321476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Adherence in specific immunotherapy].
    Lemberg ML; Joisten MJ; Mösges R
    Hautarzt; 2017 Apr; 68(4):282-286. PubMed ID: 28213675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T regulatory cells in allergen-specific immunotherapy.
    Verhagen J; Taylor A; Blaser K; Akdis M; Akdis CA
    Int Rev Immunol; 2005; 24(5-6):533-48. PubMed ID: 16318994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory cells in allergen-specific immunotherapy.
    Soyka MB; Holzmann D; Akdis CA
    Immunotherapy; 2012 Apr; 4(4):389-96. PubMed ID: 22512633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Th1-adjuvanted allergy vaccine.
    von Baehr V; Hermes A; von Baehr R; Scherf HP; Volk HD; Fischer von Weikersthal-Drachenberg KJ; Woroniecki S
    J Investig Allergol Clin Immunol; 2005; 15(4):234-41. PubMed ID: 16433203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allergen immunotherapy with cat allergen peptides.
    Kay AB; Larché M
    Springer Semin Immunopathol; 2004 Feb; 25(3-4):391-9. PubMed ID: 15007637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allergen-loaded strontium-doped hydroxyapatite spheres improve allergen-specific immunotherapy in mice.
    Garbani M; Xia W; Rhyner C; Prati M; Scheynius A; Malissen B; Engqvist H; Maurer M; Crameri R; Terhorst D
    Allergy; 2017 Apr; 72(4):570-578. PubMed ID: 27590538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allergen-specific immunotherapy: an update on immunological mechanisms of action.
    Ciprandi G; Marseglia GL; Tosca MA
    Monaldi Arch Chest Dis; 2006 Mar; 65(1):34-7. PubMed ID: 16700191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modification of the innate immune function of dendritic cells by allergen-specific immunotherapy.
    Bellinghausen I
    Clin Exp Allergy; 2010 Jan; 40(1):12-4. PubMed ID: 20205693
    [No Abstract]   [Full Text] [Related]  

  • 30. Adjuvants in Allergen-Specific Immunotherapy: Modulating and Enhancing the Immune Response.
    Zubeldia JM; Ferrer M; Dávila I; Justicia JL
    J Investig Allergol Clin Immunol; 2019; 29(2):103-111. PubMed ID: 30418155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experimental forms of allergen immunotherapy with modified allergens and adjuvants.
    Mohapatra SS; San-Juan-Vergara H; Wopfner N; Ferreira F
    Clin Allergy Immunol; 2008; 21():393-413. PubMed ID: 18828519
    [No Abstract]   [Full Text] [Related]  

  • 32. Formulations for Allergen Immunotherapy in Human and Veterinary Patients: New Candidates on the Horizon.
    Pali-Schöll I; DeBoer DJ; Alessandri C; Seida AA; Mueller RS; Jensen-Jarolim E
    Front Immunol; 2020; 11():1697. PubMed ID: 32849594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intralymphatic immunotherapy: from the rationale to human applications.
    Senti G; Johansen P; Kündig TM
    Curr Top Microbiol Immunol; 2011; 352():71-84. PubMed ID: 21725898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors influencing the allergenicity and adjuvanticity of allergens.
    Deifl S; Bohle B
    Immunotherapy; 2011 Jul; 3(7):881-93. PubMed ID: 21751956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allergen immunotherapy.
    Mannan S
    Immunotherapy; 2017 Nov; 9(15):1199-1200. PubMed ID: 29130796
    [No Abstract]   [Full Text] [Related]  

  • 36. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity.
    Focke M; Swoboda I; Marth K; Valenta R
    Clin Exp Allergy; 2010 Mar; 40(3):385-97. PubMed ID: 20210812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunological mechanisms of allergen-specific immunotherapy.
    Jutel M; Akdis CA
    Allergy; 2011 Jun; 66(6):725-32. PubMed ID: 21466562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunological mechanisms in allergen-specific immunotherapy: impact on future trends in type-1 allergy management].
    Ebner C
    Wien Med Wochenschr; 1999; 149(14-15):438-41. PubMed ID: 10584289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Role of allergen-specific immunotherapy (desensitization) for the treatment of allergies in Germany. Current situation].
    Kleine-Tebbe J; Ackermann-Simon J; Hanf G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Mar; 55(3):343-50. PubMed ID: 22373847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 100 years of immunotherapy: the Monaco charter. under the high patronage of His Serene Highness Prince Albert II of Monaco.
    Canonica GW; Baena-Cagnani CE; Compalati E; Bohle B; Bonini S; Bousquet J; Cox L; Fink-Wagner AH; González Díaz S; Jacobsen L; Passalacqua G; Pawankar R; Vieths S; Yusuf O; Zuberbier T
    Int Arch Allergy Immunol; 2013; 160(4):346-9. PubMed ID: 23183050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.